Top officials from the Trump administration’s Environmental Protection Agency (EPA) met with Bayer’s CEO, Bill Anderson, last year to discuss ongoing litigation concerning the company’s glyphosate-based herbicides, including Roundup. This meeting, held on 17 June 2025, took place just months before the administration initiated actions that appeared to bolster Bayer’s position in a significant Supreme Court case. Internal government documents obtained through a Freedom of Information Act request reveal a troubling intersection of corporate influence and regulatory action.
High-Stakes Discussions on Glyphosate
The meeting involved key figures from the EPA, including Lee Zeldin, the agency’s administrator, and Nancy Beck, the principal deputy assistant administrator in the Office of Chemical Safety and Pollution Prevention. The agenda focused on “litigation” and “supreme court action” regarding glyphosate, which has been linked to thousands of cancer claims. Bayer’s ongoing legal battles have already cost the company billions in settlements, and its strategy hinges on convincing the Supreme Court to agree with their stance that the absence of a mandated cancer warning by the EPA absolves them of liability.
Bayer’s strategy is particularly contentious, as various courts have historically rejected this preemption argument. Despite this, the Trump administration has shown consistent support for Bayer’s position, which raises serious questions about the integrity of regulatory processes.
Administration’s Support Following the Meeting
In the months following the June meeting, the Trump administration took several steps that appeared to favour Bayer. Notably, on 1 December, the solicitor general appointed by Trump urged the Supreme Court to hear Bayer’s case, which the Court subsequently agreed to on 27 April 2026. Additionally, on 18 February 2026, the White House invoked the Defense Production Act to protect the production of glyphosate herbicides, effectively shielding Bayer and similar companies from the repercussions of potential liabilities.
The company’s communications indicated that such meetings are standard regulatory practices. However, critics argue that the scale of influence exhibited by Bayer raises ethical concerns regarding the prioritisation of corporate profits over public health.
Environmental Advocates Raise Alarm
Environmental advocates have expressed grave concerns over the implications of these meetings. Nathan Donley, director of environmental health science at the Center for Biological Diversity, emphasised the alarming trend of political appointees at the EPA prioritising corporate interests over the health of American citizens. Donley stated, “When the CEO of one of the largest companies in the world is meeting with political appointees in a US regulatory office, it shows just how much power and influence these corporations have on decisions that can have very real consequences for the health of all Americans.”
Legal experts have echoed these sentiments, questioning whether ordinary citizens, particularly those affected by glyphosate products, have been afforded similar opportunities to voice their concerns to the regulators.
A Pattern of Corporate Influence
The pattern of high-level meetings between corporate leaders and government officials has raised eyebrows among experts and advocates alike. Naomi Oreskes, a Harvard professor who studies corporate influence on regulation, pointed out that such access is rarely granted to the public or advocacy groups. Zen Honeycutt, founder of Moms Across America, remarked that the coercion exerted by chemical companies on regulatory bodies is an ongoing issue, underscoring the imbalance in representation.
In light of these developments, Bayer maintains that their interactions with the EPA are standard practice and that they engage with a variety of stakeholders, including non-governmental organisations. However, the outcomes of these discussions, particularly concerning the safety and regulation of glyphosate, remain contentious.
Why it Matters
The revelations surrounding the EPA’s meeting with Bayer’s leadership illustrate a concerning trend of corporate influence over regulatory practices in the United States. As the legal battle over glyphosate continues, the implications for public health are profound. With thousands alleging harm from these products, the prioritisation of corporate interests over consumer safety raises critical ethical questions about the regulatory framework designed to protect citizens. As this case progresses, the outcomes will likely set significant precedents for environmental regulation and corporate accountability in America.
